Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

This trial is studying a specialized radiation approach called stereotactic adaptive radiation therapy (CT-STAR) in people with pancreatic cancer that is borderline removable or locally advanced. This technique uses precise, targeted radiation that adapts to the tumor's daily position — potentially allowing higher doses with fewer side effects. **You may be eligible if...** - You are 18 or older - You have been diagnosed with borderline resectable, locally advanced, or medically inoperable pancreatic cancer confirmed by biopsy or cell sample - You have received at least 2 months of chemotherapy before starting radiation - Your performance status is good (ECOG 0–1) - You have no more than 3 lymph nodes involved near the tumor **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have not received adequate lead-in chemotherapy before radiation - You are unable to briefly pause systemic therapy before starting radiation - You are pregnant Talk to your doctor to see if this trial is right for you.